阿帕替尼联合化疗治疗晚期胃癌患者的临床效果及对肿瘤标志物的影响  

Clinical Effect of Apatinib Combined with Chemotherapy in the Treatment of Patients with Advanced Gastric Cancer and Its Impact on Tumor Markers

作　　者：方丽兰 余更生[1] 林秀欣[1] FANG Lilan;YU Gengsheng;LIN Xiuxin(Department of Oncology,Jiangmen Central Hospital,Jiangmen 529030,China)

机构地区：[1]江门市中心医院肿瘤内科,广东江门529030

出　　处：《临床医学工程》2022年第2期181-182,共2页Clinical Medicine & Engineering

摘　　要：目的探讨阿帕替尼联合化疗治疗晚期胃癌患者的临床效果。方法60例晚期胃癌患者随机均分为两组,对照组予以常规化疗治疗,观察组在对照组基础上予以阿帕替尼治疗,比较两组的临床疗效、肿瘤标志物水平和不良反应。结果治疗后,观察组的疾病控制率显著高于对照组,CEA、CA199水平显著低于对照组(P<0.05).两组的不良反应发生率比较,差异无统计学意义(P>0.05)。结论阿帕替尼联合化疗治疗晚期胃癌的效果显著,可降低血清CEA、CA199水平,且未增加不良反应。Objective To explore the clinical effect of apatinib combined with chemotherapy in the treatment of patients with advanced gastric cancer. Methods 60 patients with advanced gastric cancer were randomly and equally divided into two groups. The control group was treated with conventional chemotherapy, and the observation group was treated with apatinib on the basis of the control group.The clinical efficacy, levels of tumor markers and adverse reactions were compared between the two groups. Results After treatment, the disease control rate of the observation group was significantly higher than that of the control group, and the levels of CEA and CA199 were significantly lower than those of the control group(P <0.05). No statistically significant difference was found between the two groups in the incidence of adverse reactions(P >0.05). Conclusions Apatinib combined with chemotherapy in the treatment of advanced gastric cancer has significant effect, and can reduce the levels of serum CEA and CA199 without increasing adverse reactions.

关 键 词：晚期胃癌 阿帕替尼 化疗 疗效 肿瘤标志物 不良反应 

分 类 号：R735.2[医药卫生—肿瘤]